Skip to main navigation
Skip to search
Skip to main content
University of Copenhagen Research Portal Home
Help & FAQ
Dansk
English
Home
Profiles
Research output
Research units
Press/Media
Activities
Prizes
???studenttheses???
Datasets
Search by expertise, name or affiliation
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
Niklas W. Andersson, Henrik Svanstrom, Marie Lund, Bjorn Pasternak,
Mads Melbye
Department of Clinical Medicine
13
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Comparative Safety
100%
Comparative Effectiveness
100%
Apixaban
100%
Non-valvular Atrial Fibrillation
100%
Rivaroxaban
100%
Dabigatran
100%
Confidence Interval
66%
Direct Oral Anticoagulants
33%
Hazard Ratio
33%
Major Bleeding
33%
Systemic Embolism
33%
Stroke Risk
22%
Matched Comparison
22%
Twice Daily
22%
Propensity Matching
22%
Population-based
11%
Once-daily
11%
Historical Cohort Study
11%
Propensity Score
11%
Effectiveness Outcomes
11%
New User
11%
Routine Clinical Practice
11%
Clinical Practice
11%
Nationwide Registers
11%
Denmark
11%
Safety Outcomes
11%
Pharmacology, Toxicology and Pharmaceutical Science
Rivaroxaban
100%
Dabigatran
100%
Apixaban
100%
Atrial Fibrillation
100%
Cerebrovascular Accident
33%
Bleeding
33%
Direct Oral Anticoagulant
33%
Cohort Study
11%